

Dr Harsh Vardhan
Union Minister
Ministry of Health & Family Welfare
Nirman Bhawan
New Delhi - 110011
India

4 July 2019

Dear Minister,

Re: Renewal of Pneumococcal Vaccine Support for India

We are writing in relation to the support that Gavi, the Vaccine Alliance, is providing to the Government of India for its Pneumococcal Vaccine (PCV) Programme.

Following Gavi's review of the PCV Programme during the High-Level Review Panel meeting from 29-31 January 2019, we are pleased to inform you that the annual renewal for PCV Programme support has been approved for the year 2019.

The enclosed Decision Letter states the approved 2019 vaccine doses and indicative corresponding annual amount. The letter also states that Gavi committed \$180 million for PCV support, out of a total of \$500 million for the period 2016 – 2021, as provided under Annex 6 of the Partnership Framework Agreement (PFA).

2019 represents the final year of support based on Gavi's commitment for the PCV Programme. The 2019 dose volume set out in the Decision Letter was therefore calculated based on the \$180 million allocation, as communicated in the notification letter dated 1 October 2018.

As previously, we note that the Gavi Board's decision to provide catalytic support for India's PCV programme is subject to the provisions of Annex 6 of the PFA, in particular the commitments of the Government of India to fund additional costs required as well as scale-up of the programme, and to implement the programme as set out in the approved grant performance framework.

Please do not hesitate to contact the Senior Country Manager for India, Carol Szeto (cszeto@gavi.org), if you have any questions or concerns.

We remain at your disposal for any further enquiry.

Yours sincerely,



Pascal Bijleveld,
Managing Director, Country Programmes a.i.

Cc:

PS, The Minister of Health and Family Welfare

PS, The Minister of Finance

Secretary, Ministry of Health and Family Welfare

Additional Secretary, MD NHM, Ministry of Health and Family Welfare

Joint Secretary, Ministry of Health and Family Welfare

Deputy Commissioner (Immunization); MoHFW

Deputy Commissioner (UIP), MoHFW

WHO Country Representative

UNICEF Country Representative

WHO HQ

UNICEF Programme Division

UNICEF Supply Division

India

Support for Vaccine: Pneumococcal This Decision Letter sets out the Programme Terms of a Programme.

1.	Country:	India						
2.	Vaccine grant number:	1719-IND-12d-X						
3.	Date of Decision Letter:	4 July 2019						
4.	Date of the Partnership Framework Agreement:	12 June 2015						
5.	Programme title:	New Vaccine Support (NVS), Pneumococcal , Routine						
6.	Vaccine type:	Pneumococcal						
7.	Requested product presentation and formulation of vaccine:	PCV13, 4 dose(s) per vial, LIQUID						
8.	Programme Duration:¹	2017-2019						
9.	Programme Budget (indicative):²	(subject to the terms of the Partnership Framework Agreement)						
		2017-2018	2019	2020	2021	2022	2023	Total ²
	Programme Budget (US\$)	109,749,000	70,251,000	-	-	-	-	180,000,000
10.	Vaccine introduction grant	Not applicable						
11.	Product switch grant	Not applicable						
12.	Indicative Annual Amounts:³	(subject to the terms of the Partnership Framework Agreement)						
	Type of supplies to be purchased with Gavi funds	2017-2018	2019					
	Number of vaccine doses	35,573,800	23,525,200	-				
	Annual Amounts (US\$)*	109,749,000	70,251,000	-				
<p>* The 2017, 2018 and 2019 amounts were estimated based on a price per dose of US\$3.10, US\$3.05 and US\$2.95, respectively. Changes to the number of vaccine doses to be supported due to price changes will be reflected in a Decision Letter to be issued at a later time.</p>								
13.	Procurement agency:	UNICEF						

¹ This is the entire duration of the programme.

² This is the total amount endorsed by Gavi for the entire duration of the programme.

³ This is the amount that Gavi has approved.

14. Self-procurement:	Not applicable				
15. Co-financing obligations:	Not applicable. The Gavi co-financing policy does not apply to the current Gavi support for India as the country is not required to co-finance vaccines. Special arrangements apply as per Partnership Framework Agreement Annex 6.				
16. Operational support for catch-up campaigns:	Not applicable				
17. Additional Reporting Requirements:	<table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="width: 70%;"></th> <th style="width: 30%;">Due dates</th> </tr> </thead> <tbody> <tr> <td>In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.</td> <td>To be agreed with Gavi Secretariat</td> </tr> </tbody> </table>		Due dates	In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Gavi Secretariat
	Due dates				
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Gavi Secretariat				
18. Financial clarifications:	Not applicable				
19. Other conditions:	<p>Gavi's catalytic support for India is subject to the provisions in Annex 6 of the Partnership Framework Agreement, and in particular:</p> <ul style="list-style-type: none"> - The commitments of the Government of India to provide financing to fund the additional costs required for each programme that is funded with the Partnership Support and to scale up the programmes; and - Implementation of the programmes in line with the timelines, milestones and indicators set out in the performance framework 				

Signed by,

On behalf of Gavi



Pascal Bijleveld

Managing Director, Country Programmes a.i.